SCI Abstract

search
+
Functional Radiotherapy for Non-Malignant Diseases: The Potential of Ionizing Radiation Beyond Cancer Treatment
This special issue, “Functional Radiotherapy for Non-Malignant Diseases – The Potential of Ionizing Radiation Beyond Cance...
130 Years of Radiotherapy for Nonmalignant Diseases: A Historical Overview
Radiotherapy has long been associated with the treatment of malignant tumors, yet its application in nonmalignant (benign)...
Genetic and Carcinogenic Risks of Radiotherapy for Nonmalignant Diseases
Radiotherapy is a valuable treatment option for a variety of nonmalignant diseases. As the indications for low-dose radiot...
Biological Effects of Low-Dose Radiation Therapy: From Mechanistic Aspects to Translational Approaches and Challenges
Low dose radiation therapy (LDRT) is commonly applied for its pain and symptom-relieving effects in the treatment of diffe...
Low-Dose Radiotherapy for Osteoarthritis: Current Evidence, Practical Recommendations and Future Perspectives
Osteoarthritis (OA) is a widespread degenerative joint disease with increasing prevalence in aging populations. While cons...
Periarticular Soft Tissue Disorders: Enthesopathies, Tendinopathies, and Bursitis—Pathophysiology and Radiotherapeutic Approaches
Disorders of periarticular regions, including painful shoulder syndrome, greater trochanteric pain syndrome, plantar fasci...
Radioablation for Ventricular Tachycardia: Current Evidence and Future Perspectives
Stereotactic arrhythmia radioablation (STAR) is an innovative, noninvasive technique that delivers high-dose ionizing radi...
Radiation Therapy for Non-Malignant Central Nervous System Tumors, Disorders, and Illnesses — Current Applications and Future Directions
Radiation therapy has a central role in the treatment of various malignant central nervous system tumors, including glioma...
Radiation Therapy for Benign Diseases and Premalignant Conditions
Radiation therapy (RT), traditionally reserved for malignant conditions, has emerged as a valuable tool in the management ...
Radiotherapy for Nonmalignant Eye Diseases: Graves’ Ophthalmopathy – Pseudotumor Orbitae
Michael Heinrich Seegenschmiedt: Writing – original draft, Visualization, Validation, Supervision, Project administration,...
Radiotherapy for Other Nonmalignant Diseases
Radiotherapy for benign diseases is gaining increasing significance. In 2016, about 55% of radiation treatments in Germany...
Advancing Equity, Diversity, and Inclusion in Medical Education: Implications For Radiation Oncology
Equity, diversity and inclusion (EDI) have become foundational principles across healthcare and academic institutions, wit...
Education as a Tool to Navigate Changing Technology in Radiation Oncology
Investing in emerging technologies is critical to the ongoing provision of the highest quality of evidence-based radiation...
Novel Survivorship Paradigms in Head/Neck Cancer
In 2024, the National Cancer Institute (NCI) estimates there will be more than 71,000 new diagnoses of head and neck cance...
Radiotherapy for High-Risk Prostate Cancer
Prostate cancer is the most common cancer in men in 118 countries.1 Recently, the Lancet Commission on prostate cancer rep...
Health Disparities and Inequities in Prostate Cancer Along the Continuum of Care
Prostate cancer remains one of the most commonly diagnosed malignancies worldwide, yet significant disparities and inequit...
PSMA-PET Guided Radiotherapy in Prostate Cancer: A Critical Review of Current Applications and Future Directions
Prostate cancer represents one of the most prevalent malignancies among men. Despite the growing array of therapeutic opti...
Novel biomarkers for guiding treatment for prostate cancer
Prostate cancer is the most common noncutaneous malignancy in men in the United States. In 2025, an estimated 313,780 pati...
Hypofractionation/Ultra-hypofractionation for Prostate Cancer Radiotherapy
With the evolution of radiotherapy techniques permitting reduction in fraction number from 37 to 40, down to 20 and now, f...
Advancing Prostate Cancer Treatment: A Review of CT and MR-Guided Online Adaptive Radiotherapy Techniques
Prostate cancer (PCa) is the second most common malignancy in men worldwide. Radiotherapy (RT) is a well-established manag...
The Use of Particle Therapy in Prostate Cancer
Cookies are used by this site. Cookie SettingsAll content on this site: Copyright © 2025 Elsevier B.V., its licensors, an...
Radiation Therapy in Node-Positive Prostate Cancer: Current Evidence and Future Directions
Patients diagnosed with lymph-node (LN) positive prostate cancer have historically been considered to have metastatic dise...
Elective Regional Nodal Irradiation in Prostate Cancer
Elective nodal radiotherapy (ENRT) is a commonly used strategy to eradicate micro-metastatic disease in the regional nodes...
Debate 1: Radical Prostatectomy For the Right Patient With High-Risk Prostate Cancer
By any classification system used, patients with “high-risk” prostate cancer face substantial risks of recurrence and meta...
Debate 1: High-Risk Localized Prostate Cancer: Why Combination Hormone Therapy and Radiotherapy is the Optimal Treatment Strategy for Most Men
Prostate cancer is the most common cancer and the second leading cause of cancer death among men, with an estimated 300,00...
Debate 2: Primary Localized Prostate Cancer: The Case for Whole-Gland Brachytherapy Boost
Prostate cancer (PCa) is the second most common solid tumor in men.1 Although PCa carries a high cure rate, it also remain...
Debate 2: The Case for Focal External Beam Radiation Therapy Boost Over Brachytherapy Boost for Prostate Cancer
Modern trials demonstrate excellent outcomes for men with localized prostate cancer treated with radiation therapy. Howeve...
Debate 3: Metastasis Directed Therapy in Oligometastatic Prostate Cancer
The 'oligometastatic' state, first proposed by Hellman and Weichselbaum in 1995, represents a distinct biological subset b...
Debate 3: Oligometastatic Hormone Sensitive Prostate Cancer Management: Systemic Therapy Approach
GvA: Consultancy: Roche, BMS, Astellas, Bayer, Janssen, MSD, Ipsen, Pfizer, Astra Zeneca, Merck, Lilly, Novartis; Research...
Postoperative Radiation Therapy and Controversies Regarding Hormonal Therapy in the Management of Prostate Cancer
Radical treatment, whether it is radical prostatectomy (RP) or radiotherapy (RT) provides excellent oncological outcomes i...
Load More
format_indent_increase